王小嬌

[關(guān)鍵詞] 子宮內(nèi)膜異位癥;孕三烯酮;米非司酮;受孕率

[中圖分類號(hào)] R711.71? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701（2021）20-0070-03

Analysis of the effect and safety of gestrinone+mifepristone in the treatment of endometriosis with infertility

WANG Xiaojiao

Department of Gynecology， the First People′s Hospital of Aksu Prefecture in Xinjiang， Aksu? ?843000， China

[Abstract] Objective To analyze the efficacy and safety of gestrinone+mifepristone in the treatment of endometriosis with infertility. Methods 104 patients with endometriosis and infertility who were admitted to our hospital from January 2017 to March 2019 were selected as the subjects of the study. The patients were divided into the treatment group and the control group using a digital randomization method. The control group was treated with gestrinone alone， and the treatment group was treated with gestrinone and mifepristone. The clinical efficacy， changes in various clinical indicators， pregnancy rate， and adverse reactions in the two groups were observed. Results the levels of progesterone， estradiol， and luteinizing hormone in the treatment group were better than those in the control group after treatment. The endometrial thickness of the treatment group after treatment was lower than that of the control group. The endometrial thickness of the treatment group was lower than that of the control group after treatment， and the difference between the groups was significant （P<0.05）. The total clinical effective rate obtained in the treatment group was higher than that in the control group， and the difference between the groups was significant （P<0.05）. During the follow-up period， the treatment group's pregnancy rate was higher than that in the control group， and the difference between the groups was significant （P<0.05）. The pregnancy rate of the treatment group was higher. There was no statistical difference in the incidence of adverse drug reactions between the two groups （P>0.05）. Conclusion Clinical drug application （gestrinone+ mifepristone） significantly improves the effect in treating endometriosis with infertility and increases the pregnancy rate.

[Key words] Endometriosis; Gestrinone; Mifepristone; Pregency rate

子宮內(nèi)膜異位癥（EMS）在婦科臨床較為常見(jiàn)，疾病發(fā)生會(huì)引起多種癥狀，病情嚴(yán)重或發(fā)展還能導(dǎo)致不孕，對(duì)患者身心健康都極為不利[1-2]。藥物治療是此類患者常選擇的治療方法，合理、安全的用藥方案選擇，保障治療安全性的前提下幫助患者有效控制病情、提高受孕率，是臨床人員關(guān)注的重點(diǎn)[3-4]。子宮內(nèi)膜異位癥屬于一種雌激素依賴性疾病，患者常伴有不孕，臨床治療中應(yīng)用避孕藥、睪酮類衍生物等，雖有一定的治療效果，但是長(zhǎng)期用藥會(huì)影響肝腎功能，造成損傷等[5-6]。孕三烯酮具有較強(qiáng)的抗雌激素和抗孕激素作用，能有效抑制卵巢分泌功能，使異位內(nèi)膜萎縮;米司非酮是一種合成甾體類激素，能抑制排卵，促使子宮內(nèi)膜萎縮，已廣泛應(yīng)用于子宮肌瘤、功能性出血等疾病的治療中[7-8]。本文主要研究分析子宮內(nèi)膜異位癥合并不孕，臨床應(yīng)用孕三烯酮+米非司酮治療的效果和安全性，現(xiàn)報(bào)道如下。